Glycomine News
April 16, 2025
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
October 10, 2024
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
September 18, 2024
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
March 4, 2024
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
December 11, 2023
Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
November 2, 2023
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG
October 12, 2023
Glycomine Appoints Dr. Rose Marino Chief Medical OfficerÂ
August 30, 2023
Data from Glycomine’s Ongoing Natural History Study Provides Insight into Clinical Measures and Biomarkers for PMM2-CDG
January 9, 2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
July 11, 2022
Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors
December 17, 2021